Business Context and Reporting Period
This Form 8-K Current Report from Achieve Life Sciences, Inc. (ACHV) covers events occurring on October 6, 2025. The filing details the departure of a key executive and the terms of the associated separation agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the executive compensation package:
- Severance Payment: $101,296 (prorated 2025 target bonus).
- Legal Fee Reimbursement: Up to $10,000.
- Equity Impact: Accelerated vesting of unvested time-based options granted in January 2023 and January 2024 upon termination of consultancy.
Material Changes
The primary material change is the resignation of Dr. Cindy Jacobs from her roles as Chief Medical Officer and President, effective October 6, 2025. Following her resignation, she will transition to a consultant role until the first business day after the U.S. Food and Drug Administration (FDA) approves the Company's New Drug Application (NDA) for cytisinicline.
Outlook, Risks, and Management Commentary
Management has structured the transition to ensure continuity during the critical NDA approval phase for cytisinicline. Key terms include:
- Consulting Period: Dr. Jacobs will serve as a consultant until NDA approval, with equity awards continuing to vest during this period.
- Option Extension: The post-termination exercise period for specific option grants is extended to twelve months following the termination of her consultancy.
- Regulatory Contingency: The duration of the consulting arrangement and the acceleration of certain equity vesting are contingent upon the timing of the NDA approval.
Investor Verification Checklist
- Verify the status of the cytisinicline New Drug Application (NDA) with the FDA to determine the expected duration of Dr. Jacobs' consulting role.
- Review the full Separation Agreement and Consulting Agreement when filed as exhibits to the 2025 Form 10-K for complete legal terms.
- Assess the impact of the accelerated vesting of options on the company's future dilution and stock-based compensation expenses.
- Confirm the appointment of a permanent replacement for the Chief Medical Officer and President roles.